Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intercell AG

Division of Valneva SE
www.intercell.com

Latest From Intercell AG

Appointments: ThermiGen, ReForm Biologics, Hookipa Biotech and Faron

This week’s roundup includes high-level appointments by Almirall, Hookipa Biotech and RXi Pharmaceuticals, in addition to CEO appointments by Karolinska Development and ReForm Biologics and various board announcements by companies including Faron and Redx.

Appointments BioPharmaceutical

INTERVIEW: Evotec CEO On Tears, Transparency And Trying Again

Werner Lanthaler talks to Jo Shorthouse about partnering with big pharma on drug discovery, remaining authentic, and creating the 'half pregnant' company that Evotec is today.

Strategy Research & Development

INTERVIEW: Glenmark's Buschle on how it hopes to 'BEAT' cancer

Michael Buschle, Glenmark's chief scientific officer and president (biologics), clearly values the Indian firm's "entrepreneurial culture" and "flexibility", even if it means doing cutting edge R&D with relatively smaller budgets than Big Pharma enjoys.

Gastrointestinal Cancer

World TB Day: a chance to reflect on the future

We all know about the risks of new drug development and the cost barriers to patient access to those products when they are approved. These problems are particularly acute where antibacterials are concerned, as resistance grows to even some of the most commonly used drugs, all the more so in developing countries where infectious disease takes a disproportionate toll.

Infectious Diseases India
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Transdermal
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Intercell Biomedical Research & Development AG
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Austria
  • Parent & Subsidiaries
  • Valneva SE
  • Senior Management
  • Thomas Lingelbach, CEO
    Reinhard Kandera, CFO
    Alexander von Gabain, CSO
    Staph Leavenworth Bakali, CBO
  • Contact Info
  • Intercell AG
    Phone: (43) 1-20620
    Campus Vienna Biocenter 3
    Vienna, 1030
    Austria
Advertisement
Advertisement
UsernamePublicRestriction

Register